Literature DB >> 11336609

Pharmacotherapeutic management of autism.

D J Posey1, C J McDougle.   

Abstract

There are no medications that are specifically marketed for the treatment of autism. There does exist, however, an extensive body of literature describing both open-label and controlled studies of medications in the treatment of both children and adults with autism. Some of the better-studied medications (including haloperidol and risperidone) are often efficacious in treating associated symptoms of autism but can also cause unacceptable adverse effects. Early studies of serotonin re-uptake inhibitors appear promising but may not be indicated for all age groups. Small, controlled studies of methylphenidate and clonidine indicate a possible role for these medications in the treatment of hyperactivity in autism. No medications have been proven to be efficacious in the treatment of the core social or communication impairment seen in autism. Current pharmacological management is best aimed at target symptoms that have been demonstrated to respond to medication in treatment studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336609     DOI: 10.1517/14656566.2.4.587

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children.

Authors:  Jan Philipp Schuchardt; Michael Huss; Manuela Stauss-Grabo; Andreas Hahn
Journal:  Eur J Pediatr       Date:  2009-08-12       Impact factor: 3.183

Review 2.  Acupuncture for autism spectrum disorders (ASD).

Authors:  Daniel Kl Cheuk; Virginia Wong; Wen Xiong Chen
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 3.  Risperidone for autism spectrum disorder.

Authors:  O S Jesner; M Aref-Adib; E Coren
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder.

Authors:  Avinash Desousa
Journal:  Indian J Psychol Med       Date:  2010-01

5.  Adverse effects of risperidone in children with autism spectrum disorders in a naturalistic clinical setting at siriraj hospital, Thailand.

Authors:  Vitharon Boon-Yasidhi; Pantipa Jearnarongrit; Patnaree Tulayapichitchock; Jariya Tarugsa
Journal:  Psychiatry J       Date:  2014-02-03

Review 6.  A Short Review on the Current Understanding of Autism Spectrum Disorders.

Authors:  Hye Ran Park; Jae Meen Lee; Hyo Eun Moon; Dong Soo Lee; Bung-Nyun Kim; Jinhyun Kim; Dong Gyu Kim; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2016-01-28       Impact factor: 3.261

Review 7.  Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic.

Authors:  Songhyun Lim; Sanghee Lee
Journal:  Molecules       Date:  2022-08-10       Impact factor: 4.927

8.  A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report.

Authors:  Juliana Andrea Ponton; Kim Smyth; Elias Soumbasis; Sergio Andres Llanos; Mark Lewis; Wilhelm August Meerholz; Robert Lawrence Tanguay
Journal:  J Med Case Rep       Date:  2020-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.